2 Invivoscribe 2019 | 3 Message from the CEO Dear Colleagues: Iampleasedtointroduceour2019ProductCatalogandwilltakethisopportunitytosharesomeofour2018accomplishments and some of our future plans at Invivoscribe, starting with an update on companion diagnostics. In 2018 we employed our Streamlined CDx program to quickly follow up on the 2017 FDA approval of our LeukoStrat® CDx FLT3 Mutation Assay in the US as a companion diagnostic (CDx) for patients with AML for whom the Novartis drug, midostaurin treatment is being considered, with use of this internationally standardized CDx to support two new pharmaceutical partners with two new targeted drugs. We received approval in both the US and Japan for the Astellas drug, gilteritinib, and we completed submissions in both the US and Japan for the Daiichi Sanko drug, quizartinib. We also received national reimbursement from the MHLW in Japan for this LeukoStrat® CDx. In addition, we completed development and release of the entire suite of LymphoTrack® Assays and now offer a comprehensive menu ofLymphoTrackClonalityAssays along with LymphoTracksoftware forIllumina® NGS platforms (RUO on page 43, and CE-IVD on page 28). LymphoTrack assays are used to identify and track clonal rearrangements within the antigen receptor loci (IGH, IGK, TRG, TRB). The 24 ID format (48 indices for the IGH FR1 Assay) allows customers to significantlyreducecosts,asyoucanrunanycombinationofthe7assays(upto178sampleswith14controls)simultaneously on one chip, as the accompanying bioinformatics software automatically sorts and interprets the data for each targeted region and sequence ID. Our team enjoys seeing our RUO assays also being used in concert with accompanying minimal residual disease (MRD) bioinformatics software, for the study of MRD in a wide range of hematologic malignancies, including multiple myeloma and acute lymphoblastic leukemia. These clonality assays will be submitted for review via the US FDA’s 510(k) process. Our MyAML® , MyMRD® , and MyHeme® gene panels, combined with our custom MyInformatics® bioinformatics pipeline are receiving more and more traction and use by pharmaceutical partners. They are available as RUO and/or CLIA/CAP- listed tests through our LabPMM clinical laboratories in the USA, Europe and Asia. Our continued growth and progress would not be possible without your feedback and support. We look forward to continued interaction with the research and clinical communities so we can offer you the best molecular products for decades to come. We wish you, your colleagues, and your families a joyful, productive, and successful 2019. Sincerely Yours, Meghna Bhatnagar Chief Financial Officer Meghna Bhatnagar joined Invivoscribe in 2010 as Chief Financial Officer. In this role she is responsible for leading the Invivoscribe global finance organization, along with human resources and information technology. Since her arrival, Ms. Bhatnagar has played an integral role in directing all aspects of company strategy, planning and operations. Dr. Bradley Patay, M.D. Chief Medical Officer Dr. Patay is dedicated to improving health by integrating genomic knowledge into medical care. He has authored numerous articles in this field, presented at multiple conferences and has been featured in Bloomberg Business Week. He has been head of the internal medicine section at Scripps Torrey Pines, worked as an Assistant Professor at STSI, and has been a founding member of the Board, and Vice President of the College of Genomic Medicine. Michael Vishnevetsky, Ph.D. Head of Business Development Dr. Vishnevetsky joined Invivoscribe in 2018 as the Head of Global Business Development. In this role he leads Invivoscribe’s worldwide business development efforts with focus on Pharma engagement and companion diagnostics (CDx) test development. Prior to joining Invivoscribe, Dr. Vishnevetsky held business development positions at Pacific Biosciences and Thermo Fisher Scientific with focus on utilization of Next Generation Sequencing (NGS) for diagnostics of rare disease and clinical oncology. Paul McMullin Head of Global Sales & Marketing Paul McMullin joined Invivoscribe in 2018 as the Head of Global Sales & Marketing. In this role, he leads Invivoscribe’s worldwide Sales and Marketing efforts with focus on both Diagnostic and Companion Diagnostics (CDx) products. These products are sold in over 160 Countries via a Direct Sales Organization as well as Exclusive Distributors. Prior to joining Invivoscribe, Mr. McMullin held various management roles at Hologic, Gen-Probe, QUIDEL, and American Scientific Products focused on International business. He also served as an elected member of the San Diego World Trade Center Association of San Diego. Jeffrey Edward Miller, Ph.D. Founder, Chief Scientific Officer, Chief Executive Officer & Chairman Dr. Miller is a scientist, inventor, and serial entrepreneur with more than two decades of experience founding and managing companies focused on improving the excellence of healthcare worldwide. It is his mission to provide high quality, reliable, cutting-edge reagents, tests, and bioinformatic tools to advance the fields of personalized molecular diagnostics® and personalized molecular medicine® . Executive Leadership Team